Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging

Journal of Psychopharmacology June 11, 2016 Rafael G. Dos Santos, Fermanda M Balthazar, José Carlos Bouso et al. 126 citations

Rationale: In recent decades, the use of ayahuasca (AYA) – a β-carboline- and dimethyltryptamine-rich hallucinogenic botanical preparation traditionally used by Northwestern Amazonian tribes for ritual and therapeutic purposes – has spread from South America to Europe and the USA, raising concerns about its possible toxicity and hopes of its therapeutic potential. Thus, it is important to...

Prediction error, ketamine and psychosis: An updated model

Journal of Psychopharmacology May 25, 2016 Philip R. Corlett, Garry D Honey, P. Fletcher

In 2007, we proposed an explanation of delusion formation as aberrant prediction error-driven associative learning. Further, we argued that the NMDA receptor antagonist ketamine provided a good model for this process. Subsequently, we validated the model in patients with psychosis, relating aberrant prediction error signals to delusion severity. During the ensuing period, we have developed...

Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy

Journal of Psychopharmacology April 26, 2016 Timothy Amoroso, Michael Workman 89 citations

Since the wars in Iraq and Afghanistan, posttraumatic stress disorder (PTSD) has become a major area of research and development. The most widely accepted treatment for PTSD is prolonged exposure (PE) therapy, but for many patients it is intolerable or ineffective. ±3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has recently re-emerged as a new treatment option, with...

DOI: 10.1177/0269881116642542 (opens in new tab) MDMA Meta-analysis Clinical trial Posttraumatic stress +2

Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use

Journal of Psychopharmacology April 19, 2016 Zach Walsh, Peter S. Hendricks, Stephanie D. Smith et al. 63 citations

Evidence suggests that hallucinogens may have therapeutic potential for addressing a variety of problem behaviors related to the externalizing spectrum of psychopathology, such as substance misuse and criminality. Intimate partner violence (IPV) is a prevalent form of criminal violence that is related to externalizing pathology. However, the association between hallucinogen use and IPV has not...

DOI: 10.1177/0269881116642538 (opens in new tab) Hallucinogen Poison control Psychopathology Injury prevention +4

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Journal of Psychopharmacology April 1, 2016 Matthew W Johnson, Katherine A Maclean, Michael J Caspers et al. 11 citations

Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the Salvia divinorum plant, which has been used for hallucinogenic effects. Previous research on salvinorin A pharmacokinetics likely underestimated plasma levels typically resulting from the doses administered due to inefficient vaporization and not collecting samples during peak drug effects. Six healthy...

Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting.

Journal of Psychopharmacology April 2016 Matthew J. Baggott, Jeremy Coyle, Jennifer D. Siegrist et al.

The drug 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy", "molly") is a widely used illicit drug and experimental adjunct to psychotherapy. MDMA has unusual, poorly understood socioemotional effects, including feelings of interpersonal closeness and sociability. To better understand these effects, we conducted a small (n=12) within-subjects double-blind placebo controlled study of the...

Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use.

Journal of Psychopharmacology April 2016 Stephen J. Kaar, Jason Ferris, Jon Waldron et al.

In recent years the recreational use of inhaled nitrous oxide gas (N2O) is becoming increasingly popular, yet little is known about the characteristics of its users or the effects they experience. This paper presents original research from the 2014 Global Drug Survey (GDS) (n=74,864). GDS runs the largest survey of recreational drug use in the world. The findings confirm N2O as a very common...

DOI: 10.1177/0269881116632375 (opens in new tab) Full text (opens in new tab) Nitrous oxide Addictions Anaesthetic Drugs of misuse +1

Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide

Journal of Psychopharmacology 2016 Jana Speth, Clemens Speth, Mendel Kaelen et al. 119 citations

This paper reports on the effects of LSD on mental time travel during spontaneous mentation. Twenty healthy volunteers participated in a placebo-controlled crossover study, incorporating intravenous administration of LSD (75 μg) and placebo (saline) prior to functional magnetic resonance imaging (fMRI). Six independent, blind judges analysed mentation reports acquired during structured...

DOI: 10.1177/0269881116628430 (opens in new tab) Full text (opens in new tab) Mental health Cognitive health Emotional well-being Brain research +14

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Journal of Psychopharmacology October 6, 2015 Frederick S. Barrett, Matthew W Johnson, Roland R. Griffiths 634 citations

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data...

DOI: 10.1177/0269881115609019 (opens in new tab) Psilocybin Mysticism Structural equation modeling Hallucinogen +2

Psilocybin, psychological distress, and suicidality

Journal of Psychopharmacology September 1, 2015 Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths 107 citations

Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = . 81 (. 72–. 91)), past year suicidal thinking (weighted OR = . 86 (. 78–....

DOI: 10.1177/0269881115598338 (opens in new tab) Full text (opens in new tab) Psilocybin Psychological distress Hallucinogen Clinical psychology +1

Noribogaine reduces nicotine self-administration in rats.

Journal of Psychopharmacology June 1, 2015 Qing Chang, Taleen Hanania, Deborah C. Mash et al. 26 citations

Noribogaine, a polypharmacological drug with activities at opioid receptors, ionotropic nicotinic receptors, and serotonin reuptake transporters, has been investigated for treatment of substance abuse-related disorders. Smoking cessation has major benefits for both individuals and society, therefore the aim of this study was to evaluate the potential of noribogaine for use as a treatment for...

DOI: 10.1177/0269881115584461 (opens in new tab) Full text (opens in new tab) Food self-administration Nicotine addiction treatment Noribogaine pharmacology Behavioral specificity

Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or ‘ecstasy’ and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices

Journal of Psychopharmacology May 18, 2015 Sunjeev K. Kamboj, Emma J. Kilford, Stephanie Minchin et al. 43 citations

3,4-methylenedioxy- N-methylamphetamine (MDMA) produces diverse pro-social effects. Cognitive training methods rooted in Eastern contemplative practices also produce these effects through the development of a compassionate mindset. Given this similarity, we propose that one potential mechanism of action of MDMA in psychotherapy is through enhancing effects on intrapersonal attitudes (i.e....

DOI: 10.1177/0269881115587143 (opens in new tab) Ecstasy MDMA Psychopharmacology Recreational drug +3

Intimate insight: MDMA changes how people talk about significant others

Journal of Psychopharmacology April 29, 2015 Matthew J. Baggott, Matthew G. Kirkpatrick, Gillinder Bedi et al. 69 citations

Rationale: ±3,4-methylenedioxymethamphetamine (MDMA) is widely believed to increase sociability. The drug alters speech production and fluency, and may influence speech content. Here, we investigated the effect of MDMA on speech content, which may reveal how this drug affects social interactions. Method: Thirty-five healthy volunteers with prior MDMA experience completed this two-session,...

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation.

Journal of Psychopharmacology April 1, 2015 Peter H. Addy, Albert Garcia‐romeu, Matthew Metzger et al. 38 citations

This study examined the overall psychological effects of inebriation facilitated by the naturally-occurring plant hallucinogen Salvia divinorum using a double-blind, randomized, placebo-controlled trial. Thirty healthy individuals self-administered Salvia divinorum via combustion and inhalation in a quiet, comfortable research setting. Experimental sessions, post-session interviews, and 8-week...

Prosocial effects of MDMA: A measure of generosity

Journal of Psychopharmacology March 4, 2015 Matthew G. Kirkpatrick, Andrew W. Delton, Theresa E. Robertson et al. 86 citations

Background: 3,4-methylenedioxymethamphetamine (MDMA) produces “prosocial” effects that contribute to its recreational use. Few studies have examined the cognitive and behavioral mechanisms by which MDMA produces these effects. Here we examined the effect of MDMA on a specific prosocial effect, i.e. generosity, using a task in which participants make decisions about whether they or another...

DOI: 10.1177/0269881115573806 (opens in new tab) MDMA Generosity Prosocial behavior Developmental psychology +2

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of Psychopharmacology March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

Psychedelics not linked to mental health problems or suicidal behavior: A population study

Journal of Psychopharmacology March 1, 2015 Pål-ørjan Johansen, Teri Suzanne Krebs 300 citations

A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental...

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

Journal of Psychopharmacology February 17, 2015 Níall Lally, Allison C. Nugent, David A. Luckenbaugh et al. 224 citations

Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists. In this exploratory re-analysis, we assessed whether administration of rapid-acting antidepressant ketamine was associated specifically with reduced anhedonia in medication-free treatment-refractory patients with major depressive...

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

Journal of Psychopharmacology February 9, 2015 Tomislav Majić, Timo T Schmidt, Jürgen Gallinat 267 citations

Interest in the therapeutic potential of psychedelic substances has recently resumed. During an early phase of human psychedelic research, their therapeutic application in different pathologies had been suggested, and the first evidence for efficacy was provided. The range of recent clinical applications of psychedelics spans from cluster headaches and obsessive-compulsive disorder to addiction...

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Journal of Psychopharmacology January 13, 2015 Michael P. Bogenschutz, Alyssa A. Forcehimes, Jessica Pommy et al. 1,164 citations

Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of...

DOI: 10.1177/0269881114565144 (opens in new tab) Psilocybin Alcohol Hallucinogen Proof of concept

Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity

Journal of Psychopharmacology January 8, 2015 JHP van Wel, DB Spronk, Kim P. C. Kuypers et al. 23 citations

Trait impulsivity has been linked to addiction in humans. It has been suggested that drug users with high trait impulsivity levels are more sensitive to subjective drug intoxication. This study assessed whether subjective response to drugs differs between drug users with normal or high levels of trait impulsivity. Regular drug users (N = 122) received doses of cocaine HCl, cannabis, and placebo...

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Journal of Psychopharmacology November 11, 2014 Peter Gasser, Katharina Kirchner, Torsten Passie 458 citations

Objective: A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up. Method: 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A...

DOI: 10.1177/0269881114555249 (opens in new tab) Anxiety Psychotherapist Situational ethics Clinical psychology +1

Treating drug dependence with the aid of ibogaine: a retrospective study.

Journal of Psychopharmacology November 1, 2014 Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, Bruno Rasmussen Chaves et al. 110 citations

Ibogaine is an alkaloid purported to be an effective drug dependence treatment. However, its efficacy has been hard to evaluate, partly because it is illegal in some countries. In such places, treatments are conducted in underground settings where fatalities have occurred. In Brazil ibogaine is unregulated and a combined approach of psychotherapy and ibogaine is being practiced to treat...

Resting state functional magnetic resonance imaging reveals distinct brain activity in heavy cannabis users - a multi-voxel pattern analysis.

Journal of Psychopharmacology November 2014 H Cheng, Patrick D. Skosnik, Ben J Pruce et al.

Chronic cannabis use can cause cognitive, perceptual and personality alterations, which are believed to be associated with regional brain changes and possible changes in connectivity between functional regions. This study aims to identify the changes from resting state functional magnetic resonance imaging scans. A two-level multi-voxel pattern analysis was proposed to classify male cannabis...

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Journal of Psychopharmacology September 11, 2014 Mary P Cosimano, Matthew W. Johnson, Albert Garcia‐romeu et al. 910 citations

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a...